Pacemaker implantation for heart failure does not benefit nearly half of the patients

June 13, 2011

A new meta-analysis study, led by physician researchers at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine, and to be published in the Archives of Internal Medicine (embargoed until June 13, 4 p.m. EDT), shows that three-lead cardiac pacemakers implanted in those with heart failure fail to help up to 40 percent of patients with such devices.

"These findings have significant clinical implications and impact tens of thousands of patients in the U.S.," said Ilke Sipahi, MD, Associate Director of Heart Failure and Transplantation at UH Case Medical Center and Assistant Professor at Case Western Reserve University School of Medicine. "In this in-depth analysis, we found that pacemaker patients with less severe electrical disturbance in their hearts did not receive any benefit whatsoever from these expensive and potentially risky implants. Given the abundance of data showing lack of efficacy in this patient population, current treatment guidelines should be changed."

Dr. Sipahi, along with James Fang, MD, Director, Clinical Cardiovascular Services at UH Case Medical Center and Professor at Case Western Reserve University School of Medicine, investigated the treatment method known as cardiac resynchronization therapy (CRT). This highly sophisticated treatment technique involves pacing both ventricles of the heart in an attempt to correct the impaired synchrony during contraction of the heart.

Sometimes also referred to as "biventricular pacing," CRT is a form of therapy for congestive heart failure that utilizes a special pacemaker to re-coordinate the action of the heart chambers.

The study is a combined analysis of clinical trials of nearly 6,000 patients and examines whether the current criteria used by the medical community in selecting patients for the treatment are appropriate.

Treatment guidelines endorsed by various professional societies recommend these pacemakers for patients with heart failure symptoms due to weak heart muscles that have a specific abnormality on the electrocardiogram (EKG) known as QRS prolongation. Current treatment guidelines recommend that heart failure patients with QRS prolongation to greater than 0.12 seconds should get these devices.

However, the new meta-analysis demonstrates that patients do not have a survival benefit or a reduction in hospitalizations from these pacemakers, unless their QRS is prolonged to greater than 0.15 seconds, a threshold much greater than the 0.12 second cutoff advocated in the treatment guidelines. Approximately 40 percent of patients receiving these devices have a QRS prolongation in the range of 0.12 to 0.15 seconds and do not get any benefit from pacemaker therapy according to the results of the new study.

"This study can have profound impact on minimizing unnecessary procedures" added Dr. Sipahi. "Revising the criteria for implantation of these devices will help avoid thousands of unnecessary implants and will also lead to cutting down on unwarranted costs."

In contrast, the tandem's research also confirmed that patients with QRS prolongation greater 0.15 seconds got substantial benefit from their devices, lived longer and were hospitalized less often.

Heart failure, especially at its advanced stages, is a deadly disease affecting approximately 6 million Americans. Annual costs related to heart failure approached $40 billion in 2010. The global CRT devices market is expected to reach at $2.8 billion by 2015 with the North American segment accounting for nearly 40 percent of the global value.

"Our analysis suggests that this important therapy appears to benefit primarily those patients with the greatest prolongation in the QRS duration," said Fang. "This study may help to better select patients who are most likely to benefit from this effective but costly procedure."
-end-
About University Hospitals

University Hospitals serves the needs of patients through an integrated network of hospitals, outpatient centers and primary care physicians. At the core of our health system is University Hospitals Case Medical Center. The primary affiliate of Case Western Reserve University School of Medicine, University Hospitals Case Medical Center is home to some of the most prestigious clinical and research centers of excellence in the nation and the world, including cancer, pediatrics, women's health, orthopedics and spine, radiology and radiation oncology, neurosurgery and neuroscience, cardiology and cardiovascular surgery, organ transplantation and human genetics. Its main campus includes the internationally celebrated UH Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; UH MacDonald Women's Hospital, Ohio's only hospital for women; and UH Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. For more information, go to www.uhhospitals.org

University Hospitals Case Medical Center

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.